Regular Article
Breast Cancer Resistance Protein Directly Confers SN-38 Resistance of Lung Cancer Cells

https://doi.org/10.1006/bbrc.2001.4267Get rights and content

Abstract

Breast cancer resistance protein (BCRP), an ABC half-transporter, is overexpressed in cancer cell lines selected with doxorubicin/verapamil, topotecan, or mitoxantrone. BCRP-overexpressing cells show cross-resistance to camptothecin derivatives such as irinotecan, SN-38 (the active metabolite of irinotecan), and topotecan. To test whether BCRP confers SN-38 resistance, we selected two SN-38 resistant sublines from PC-6 human small-cell lung cancer cells by SN-38, and then characterized these cells. Compared to PC-6 cells, the resistant sublines PC-6/SN2-5 and PC-6/SN2-5H were approximately 18- and 34-fold resistant, respectively. The intracellular SN-38 accumulation was reduced in the sublines, and BCRP mRNA was overexpressed in proportion to the degree of SN-38 resistance. These findings suggest that BCRP confers SN-38 resistance in the sublines. To confirm this hypothesis, PC-6/SN2-5 cells were transfected with antisense oligonucleotides complementary to portions of BCRP mRNA. The antisense oligonucleotides significantly suppressed BCRP mRNA expression, and enhanced SN-38 sensitivity in the subline. These data indicate that BCRP is directly involved with SN-38 resistance, by efflux transport of SN-38.

References (37)

  • S.K. Rabindran et al.

    Fumitremorgin C reverses multidrug resistance in cells transfected with the breast cancer resistance protein

    Cancer Res.

    (2000)
  • R. Allikmets et al.

    A human placenta-specific ATP-binding cassette gene (ABCP) on chromosome 4q22 that is involved in multidrug resistance

    Cancer Res.

    (1998)
  • K. Miyake et al.

    Molecular cloning of cDNAs which are highly overexpressed in mitoxantrone-resistant cells: Demonstration of homology to ABC transport genes

    Cancer Res.

    (1999)
  • D.D. Ross et al.

    Atypical multidrug resistance: Breast cancer resistance protein messenger RNA expression in mitoxantrone-selected cell lines

    J. Natl. Cancer Inst.

    (1999)
  • J.D. Allen et al.

    The mouse Bcrp1/Mxr/Abcp gene: Amplification and overexpression in cell lines selected for resistance to topotecan, mitoxantrone, or doxorubicin

    Cancer Res.

    (1999)
  • M. Maliepaard et al.

    Overexpression of the BCRP/MXR/ABCP gene in a topotecan-selected ovarian tumor cell line

    Cancer Res.

    (1999)
  • L.A. Hazlehurst et al.

    Multiple mechanisms confer drug resistance to mitoxantrone in the human 8226 myeloma cell line

    Cancer Res.

    (1999)
  • S.K. Rabindran et al.

    Reversal of a novel multidrug resistance mechanism in human colon carcinoma cells by fumitremorgin C

    Cancer Res.

    (1998)
  • Cited by (241)

    • Predicting disruptions to drug pharmacokinetics and the risk of adverse drug reactions in non-alcoholic steatohepatitis patients

      2023, Acta Pharmaceutica Sinica B
      Citation Excerpt :

      Consequently, higher irinotecan levels will lead to higher SN-38 levels in the plasma. Moreover, SN-38 is a substrate of transporters that are affected by NASH, including OATP1B1, OATP1B3, MRP2, P-gp, and BCRP591–597. This may also result in changes in SN-38 pharmacokinetics even though UGT1A1, the main enzyme in charge of SN-28 metabolism598–601, does not seem to be affected by NASH disease287.

    • Predictive biomarkers of drug resistance in colorectal cancer—Recent updates

      2020, Drug Resistance in Colorectal Cancer: Molecular Mechanisms and Therapeutic Strategies
    • Cancer chemoresistance; Biochemical and molecular aspects: A brief overview

      2016, European Journal of Pharmaceutical Sciences
      Citation Excerpt :

      Each BCRP monomer consists of one transmembrane domain, six transmembrane segments and one nucleotide-binding domain at the N-terminal (Xu et al., 2004). BCRP transports various drugs, including tyrosine kinase inhibitors, anthracyclines, daunorubicin, doxorubicin, etoposide, topotecan, prazosin, mitoxantrone, methotrexate, SN-38 and, also endogenous compounds such as sterols and riboflavin (Kawabata et al., 2001; Özvegy-Laczka et al., 2005; Maliepaard et al., 2001; Robey et al., 2001; Honjo et al., 2001; Zhao and Goldman, 2003). The available amount of drug that can affect the target will decrease via detoxification.

    View all citing articles on Scopus
    1

    To whom correspondence should be addressed at Second Department of Internal Medicine, Nagasaki University School of Medicine, 1-7-1 Sakamoto, Nagasaki 852-8501, Japan. Fax: +81-(95)-849-7285. E-mail: [email protected].

    View full text